What is the recommended diagnostic workup, risk stratification, and treatment strategy for a patient with suspected myelodysplastic syndrome?

Myelodysplastic Syndrome: Diagnostic Workup, Risk Stratification, and Treatment Strategy

For suspected MDS, perform bone marrow aspirate and biopsy with morphologic assessment, cytogenetics, flow cytometry, and comprehensive next-generation sequencing myeloid mutation panel, then stratify risk using IPSS-R or IPSS-M to guide treatment selection between supportive care/disease-modifying agents for lower-risk disease versus hypomethylating agents or allogeneic stem cell transplantation for higher-risk disease 1, 2.

Diagnostic Workup

The diagnosis requires morphological evidence of dysplasia on bone marrow examination. You must obtain:

• Bone marrow aspirate and biopsy with iron staining to assess ring sideroblasts
• Cytogenetic analysis (karyotype and FISH) to identify chromosomal abnormalities
• Flow cytometry to evaluate dysplastic features and blast percentage
• Next-generation sequencing myeloid mutation panel to identify prognostic mutations (>40 recurrent mutations described, including SF3B1, TP53, ASXL1, RUNX1, and others) 1, 3

Peripheral blood findings show cytopenias (anemia, neutropenia, and/or thrombocytopenia), but these alone are insufficient for diagnosis 4.

Risk Stratification

Use the Revised International Prognostic Scoring System (IPSS-R) or the molecular IPSS-M as your primary risk stratification tools 1, 3. Both incorporate:

• Peripheral blood cytopenias (depth and number)
• Bone marrow blast percentage
• Cytogenetic abnormalities

The IPSS-M additionally integrates somatic mutations, providing more refined prognostication 3, 5. This stratification divides patients into:

• Lower-risk: Very low, low, and some intermediate-risk (median survival 3-10 years)
• Higher-risk: High and very high-risk (median survival <3 years) 4

Critical caveat: TP53 mutations confer particularly poor prognosis and resistance to standard therapies, requiring intensified surveillance and consideration for clinical trials 2, 5.

Treatment Strategy

Lower-Risk MDS

Treatment goals focus on reducing transfusion burden, improving quality of life, and delaying progression 2, 3.

For Symptomatic Anemia:

Without del(5q):

• First-line: Erythropoiesis-stimulating agents (ESAs) - specifically EPO alpha at 30,000-80,000 units weekly or darbepoetin 150-300 mcg weekly

  • Best response when serum EPO <200-500 U/L and minimal transfusion requirements
  • Achieves 40-60% response rate with median duration 20-24 months
  • Response occurs within 8-12 weeks 2
  • Adding G-CSF improves efficacy 2

• After ESA failure in MDS with ring sideroblasts (MDS-RS) or SF3B1 mutation:

  • Luspatercept - achieves 38-63% transfusion independence in phase II/III trials 2
  • This is now a preferred second-line option 2

With del(5q):

• Lenalidomide 10 mg daily for 3 weeks every 4 weeks is first-line (after ESA failure/ineligibility in Europe)
  • Achieves 60-65% response rate with median transfusion independence of 2-2.5 years
  • Produces cytogenetic response in 50-75% of patients 2
  • Warning: Monitor closely for grade 3-4 neutropenia/thrombocytopenia in first weeks; dose reduce or add G-CSF as needed 2
  • Critical: TP53 mutations predict lenalidomide resistance and higher AML progression risk - these patients need intensified surveillance 2

For Symptomatic Thrombocytopenia:

• Platelet transfusions as needed
• Consider thrombopoietin receptor agonists (romiplostim, eltrombopag) only if marrow blasts <5% - not approved but may have efficacy 2

For Symptomatic Neutropenia:

• Broad-spectrum antibiotics immediately for fever/infection
• Short-term G-CSF during severe infections 2

Higher-Risk MDS

Treatment goals prioritize prolonging survival 2, 3.

For patients <70 years without major comorbidities:

• Allogeneic stem cell transplantation is the only curative therapy and should be offered to all eligible patients with a donor 2
• Consider cytoreduction with hypomethylating agents or AML-like chemotherapy when marrow blasts ≥10% before transplant 2

For transplant-ineligible patients:

• Azacitidine is the preferred first-line therapy - the only agent proven to improve survival in higher-risk MDS 2
• Alternative: Decitabine or oral decitabine/cedazuridine 3
• For fit patients <70 years with favorable cytogenetics and marrow blasts ≥10%: Consider AML-like intensive chemotherapy as bridge to transplant 2

After hypomethylating agent failure: No approved therapies exist; consider clinical trials or allogeneic transplantation if now eligible 3.

Supportive Care Considerations

Iron Chelation:

Strongly recommended for:

• All allogeneic transplant candidates (even moderate iron overload increases transplant-related mortality) 2
• Lower-risk MDS patients with major iron overload (cardiac T2* <20 milliseconds on MRI, or >70-80 RBC units transfused) 2

Consider starting when:

• Serum ferritin >1000-2500 U/L or after 20-60 RBC concentrates in lower-risk patients with favorable prognosis 2

Use oral deferasirox (avoid in renal failure) or parenteral deferoxamine 2.

Transfusion Strategy:

• Maintain hemoglobin threshold ≥8 g/dL (9-10 g/dL with comorbidities)
• Transfuse sufficient RBC units to raise hemoglobin >10 g/dL to limit chronic anemia effects on quality of life 2

Key Clinical Pitfalls

1. Don't use prophylactic antibiotics or G-CSF for neutropenia - only treat active infections 2
2. Don't use thrombopoietin receptor agonists if marrow blasts ≥5% - increased leukemia risk 2
3. IPSS-R intermediate-risk patients require individualized decisions based on age, comorbidities, cytopenia severity, and mutations - they may be treated as either lower or higher-risk 2
4. TP53-mutated patients have poor outcomes with standard therapies - prioritize clinical trials and early transplant evaluation 5